沃森生物：公司的生物制造业务在2026年一季度实现投产

Core Insights - The company announced that its biomanufacturing business will complete the capacity construction of its first industrialization project by 2025 and is expected to commence production in the first quarter of 2026 [1] - The company has established partnerships with downstream customers and is actively engaging with them [1] - The company's quadrivalent meningococcal vaccine is currently in Phase III clinical trials, and it will strictly adhere to national drug registration procedures and regulations [1]